propranolol accord 40 mg
accord healthcare b.v. - propranololhydroklorid - tablett, filmdrasjert - 40 mg
pranolol 40 mg
actavis group ptc ehf (1) - propranololhydroklorid - tablett - 40 mg
propranolol accord 10 mg
accord healthcare b.v. - propranololhydroklorid - tablett, filmdrasjert - 10 mg
propranolol accord 80 mg
accord healthcare b.v. - propranololhydroklorid - tablett, filmdrasjert - 80 mg
pranolol 20 mg
actavis group ptc ehf (1) - propranololhydroklorid - tablett - 20 mg
pranolol 80 mg
actavis group ptc ehf (1) - propranololhydroklorid - tablett - 80 mg
hemangiol
pierre fabre medicament - propranolol hydroklorid - hemangiom - betablokkende midler - hemangiol is indicated in the treatment of proliferating infantile haemangioma requiring systemic therapy: , life- or function-threatening haemangioma,, ulcerated haemangioma with pain and/or lack of response to simple wound care measures,, haemangioma with a risk of permanent scars or disfigurement. , it is to be initiated in infants aged 5 weeks to 5 months.
namuscla
lupin europe gmbh - mexiletine hydrochloride - myotonic lidelser - hjertetapi - namuscla er indikert for symptomatisk behandling av myotonia hos voksne pasienter med ikke-dystrophic myotonic lidelser.
rimstar
sandoz - københavn - rifampicin / isoniazid / pyrazinamid / etambutolhydroklorid - tablett, filmdrasjert - 150 mg / 75 mg / 400 mg / 275 mg
zeposia
bristol-myers squibb pharma eeig - ozanimod hydrochloride - multiple sclerosis, relapsing-remitting; colitis, ulcerative - immunsuppressive - multiple sclerosiszeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features. ulcerative colitiszeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.